Replimune Group マネジメント

マネジメント基準チェック /24

Replimune Groupの CEO はSush Patelで、 Apr2024年に任命され、の在任期間は 2.33年です。の年間総報酬は$ 5.85Mで、 12%給与と88%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.14%を直接所有しており、その価値は€ 1.75M 。経営陣と取締役会の平均在任期間はそれぞれ2.3年と5.5年です。

主要情報

Sush Patel

最高経営責任者

US$5.8m

報酬総額

CEO給与比率	11.97%
CEO在任期間	2.3yrs
CEOの所有権	0.1%
経営陣の平均在職期間	2.3yrs
取締役会の平均在任期間	5.5yrs

経営陣の近況

Recent updates

CEO報酬分析

Replimune Group の収益と比較して、Sush Patel の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2026	US$6m	US$700k	-US$314m
Dec 31 2025	n/a	n/a	-US$315m
Sep 30 2025	n/a	n/a	-US$310m
Jun 30 2025	n/a	n/a	-US$280m
Mar 31 2025	US$4m	US$600k	-US$247m
Dec 31 2024	n/a	n/a	-US$228m
Sep 30 2024	n/a	n/a	-US$213m
Jun 30 2024	n/a	n/a	-US$220m
Mar 31 2024	US$2m	US$465k	-US$216m
Dec 31 2023	n/a	n/a	-US$210m
Sep 30 2023	n/a	n/a	-US$199m
Jun 30 2023	n/a	n/a	-US$182m
Mar 31 2023	US$3m	US$447k	-US$174m
Dec 31 2022	n/a	n/a	-US$157m
Sep 30 2022	n/a	n/a	-US$147m
Jun 30 2022	n/a	n/a	-US$133m
Mar 31 2022	US$7m	US$394k	-US$118m

報酬と市場: Sushの総報酬 ($USD 5.85M ) は、 German市場 ($USD 1.91M ) の同規模の企業の平均を上回っています。

報酬と収益: Sushの報酬は増加しましたが、会社は利益を上げていません。

CEO

Sush Patel (55 yo)

2.3yrs

在職期間

US$5,845,982

報酬

Dr. Sushil Patel, also known as Sush, Ph D., is Independent Director of Revolution Medicines, Inc. from June 16, 2022. Dr. Patel is CEO & Director of Replimune Group, Inc. from April 1, 2024.Dr. Patel ser...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Sushil Patel	CEO & Director	2.3yrs	US$5.85m	0.14% € 1.8m
Emily Hill	Chief Financial Officer	2.9yrs	US$2.09m	0.070% € 859.6k
Konstantinos Xynos	Chief Medical Officer	3.7yrs	US$2.11m	0.073% € 904.5k
Philip Astley-Sparke	Executive Chairman	11.6yrs	US$6.02m	1.58% € 19.5m
Andrew Schwendenman	Chief Accounting Officer & Treasurer	3.3yrs	データなし	0.030% € 365.1k
Shawn Glidden	Senior VP & General Counsel	1.5yrs	データなし	データなし
Camilo Garcia	Chief Human Resource Officer	1.5yrs	データなし	データなし
Paul Bullock	Chief Manufacturing Officer & Framingham Site Head	2.6yrs	データなし	データなし
Nina Aragam	Senior Vice President of Portfolio Strategy & Program Management	1.5yrs	データなし	データなし
Carolyn Trott	Senior Vice President of Quality Assurance	2.3yrs	データなし	データなし
Kari Jeschke	Senior Vice President of Regulatory Affairs	1.5yrs	データなし	データなし

2.3yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: 7R8の経営陣は経験豊富であると考えられます ( 2.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Sushil Patel	CEO & Director	2.3yrs	US$5.85m	0.14% € 1.8m
Philip Astley-Sparke	Executive Chairman	11.6yrs	US$6.02m	1.58% € 19.5m
Joseph Slattery	Independent Director	8.8yrs	US$251.11k	0.0079% € 97.7k
Michael Goller	Independent Director	1.4yrs	US$50.00k	0% € 0
Paolo Pucci	Independent Director	6.3yrs	US$236.11k	0% € 0
Madhavan Balachandran	Independent Director	1.9yrs	US$231.11k	0% € 0
Kapil Dhingra	Independent Director	9.1yrs	US$246.11k	0% € 0
Christy Oliger	Independent Director	4.7yrs	US$246.11k	0% € 0
Dieter Weinand	Lead Independent Director	8.2yrs	US$278.61k	0% € 0
Veleka Peeples-Dyer	Independent Director	3.2yrs	US$238.61k	0% € 0

5.5yrs

平均在職期間

58.5yo

平均年齢

経験豊富なボード: 7R8の取締役会は経験豊富であると考えられます ( 5.5年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/08/14 05:48
終値	2026/08/14 00:00
収益	2026/06/30
年間収益	2026/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Replimune Group, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。13

アナリスト	機関
Clarence Powell	BMO Capital Markets Equity Research
Evan Seigerman	BMO Capital Markets Equity Research
Guyn Kim	BMO Capital Markets Equity Research

Replimune Group マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Replimune Group, Inc. Announces Appointment of Michelle Dinapoli to Chief Commercial Officer, Effective August 18, 2026

CEO & Director recently sold €442k worth of stock

Replimune Group, Inc., Annual General Meeting, Sep 15, 2026

Replimune Group, Inc., Annual General Meeting, Sep 03, 2025

Replimune Group, Inc. Appoints Michael Goller to Its Board of Directors

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Recent updates

Replimune Group, Inc. Announces Appointment of Michelle Dinapoli to Chief Commercial Officer, Effective August 18, 2026

CEO & Director recently sold €442k worth of stock

New minor risk - Shareholder dilution

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $149.999956 million.

Robbins LLP Informs Investors of the Replimune Group, Inc. Class Action

Replimune Announces Favorable Outcome of FDA Advisory Committee Meeting for RP1 in Advanced Melanoma

Replimune Group, Inc., Annual General Meeting, Sep 15, 2026

Replimune Group, Inc. Announces U.S. Food and Drug Administration Acceptance Of RP1 Biologics License Application Resubmission For Advanced Melanoma

Now 21% overvalued after recent price rise

Replimune Group Presents Three-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial of RP1 Plus Nivolumab in Patients with Anti-PD-1-Failed Melanoma

Replimune Group Announces Planned RP1 BLA Resubmission Following Discussion With FDA

Now 22% undervalued after recent price drop

Replimune Group, Inc. Receives Complete Response Letter From FDA For RP1 Biologics License Application For Treatment Of Advanced Melanoma

Replimune Group, Inc. Presents Late-Breaking Abstract and Additional Posters on Rp1 At 40Th Annual Meeting of the Society for the Immunotherapy of Cancer (Sitc 2025)

Replimune Group, Inc. Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma Prescription Drug User Fee Act (PDUFA) Target Action Date Set for April 10, 2026

Replimune Group, Inc. Highlights Acral Melanoma Data for Rp1 Plus Nivolumab At the ESMO Congress 2025

Replimune Provides Update Following Type A Meeting with FDA

Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman

Replimune Group, Inc., Annual General Meeting, Sep 03, 2025

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Replimune Group, Inc

Replimune Group, Inc. Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

Replimune Group, Inc. Presents New Analyses from the Ignyte Study of Rp1 Plus Nivolumab in Anti-Pd-1 Failure Melanoma At the 2025 American Society of Clinical Oncology Annual Meeting

Replimune Group, Inc. to Report Q4, 2025 Results on May 22, 2025

Replimune Group, Inc. Appoints Michael Goller to Its Board of Directors

Replimune Group, Inc. Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Executive Chairman recently sold €226k worth of stock

Replimune Group, Inc. Announces Management Changes

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

No longer forecast to breakeven

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

CEO & Director recently sold €298k worth of stock

No longer forecast to breakeven

Insufficient new directors

Replimune Group, Inc. Announces Executive Appointments

Now 23% undervalued

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune Group, Inc., Annual General Meeting, Sep 07, 2022

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 2000 Growth Index

Replimune Group, Inc. Announces the Resignation of Jason Rhodes from Its Board of Directors

Chief Commercial Officer recently sold €150k worth of stock

Replimune Group, Inc. Announces Updated Data from Completed Cohorts of the Phase 2 Part of the IGNYTE Clinical Trial in Non-Melanoma Skin Cancer (Nmsc) and Melanoma

Replimune Group, Inc. Announces Departure of Dr. Otello Stampacchia from its Board of Directors

Now 22% undervalued after recent price drop

Chief Medical Officer Andrea Pirzkall has left the company

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 3000E Index

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

Forecast to breakeven in 2026

Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma

New 90-day low: €30.40

Replimune Group, Inc. Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

マネジメント基準チェック /24